Treatment with flecainide for symptomatic and refractory tachyarrhythmias in children

9 children (aged 2.5 months to 16 years, 4 boys, 5 girls) presenting with symptomatic and refractory tachyarrhythmias (7 supraventricular, 2 ventricular; 3 with structural cardiac abnormalities).

Intravenous flecainide (dose required to terminate ranged from 1.0 to 2.4 mg/kg, mean 1.55 mg/kg), followed by maintenance oral flecainide (6.7-9.5 mg/kg per day in three divided doses) in 8 patients.

Termination of arrhythmias and maintenance of sustained sinus rhythm